Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845703 | 0.77 | CCR1 (0.38) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL30529332 | 0.76 | CCR1 (0.50) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL748190 | 0.76 | CCR1 (0.50) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL2894661 | 0.75 | CCR1 (0.45) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL30241147 | 0.73 | TRIM24 (0.52) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL30390711 | 0.72 | CCR1 (0.42) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL26880654 | 0.72 | CCR1 (0.42) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL28868517 | 0.71 | TRIM24 (0.53) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL29950826 | 0.71 | CCR1 (0.45) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL19139612 | 0.71 | CCR1 (0.45) | CCR1CCR5CCR8TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | CCR1 484/4885CCR5 363/4885CCR8 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.